H.R. 8205
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Summary:
• Extends the authorization of the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031 (previously authorized through 2026)
• Requires clinical trial status reviews for grant renewals, including assessment of patient enrollment data and requests for interim clinical trial data from manufacturers
• Mandates the FDA Commissioner to publish a report within one year containing an updated 5-year action plan and a review of the 2022 Action Plan implementation
• Requires clinical trial status reviews for grant renewals, including assessment of patient enrollment data and requests for interim clinical trial data from manufacturers
• Mandates the FDA Commissioner to publish a report within one year containing an updated 5-year action plan and a review of the 2022 Action Plan implementation